SLC5A2 and diabetes mellitus: However, treatment options for DM are expanding, with glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) first approved in the US for DM treatment in 2005 and 2014, respectively [13, 14].